Technology allows physicians to 'See More' and reduce the number of painful and costly biopsies performed
MISSISSAUGA, ON, Feb. 8, 2012 /CNW/ - MedX Health Corp., (TSXV: MDX) a global leader in drug free, non-invasive low level laser light therapy
and light imaging systems, announced today that MoleMate™, has received
approval from Health Canada, and is immediately available and in stock
for all Canadian physicians, joining their colleagues in Europe, the
UK, Australia, and the US, who have been utilizing this new pain-free,
non-invasive imaging system to 'see more', approximately 2mm below the
surface of suspicious moles, and provide additional information and
images related to every mole and all types of melanomas and
MoleMate uses a patented device and technology that features a hand-held
scanner designed for office use that utilizes light to view beneath
suspicious moles or lesions in a pain free, non-invasive manner,
creating images for physicians to evaluate all types of moles and
lesions within seconds, providing images that can reveal if a mole is
benign, or something more serious, often eliminating the need for skin
biopsies, resulting in less pain, scarring, and expense. Physicians
interested in learning more should contact MedX Health Corp. at www.simsys-molemate.com.
"We are excited about launching MoleMate and the expanded features
version, SIMSYS™, and introducing Canadian physicians to this amazing
technology, that had previously only been available outside Canada in
the US, Australia, Europe and the United Kingdom. In the last quarter
of 2011 we began selling into the US market which is estimated to be a
$1 Billion dollar opportunity, based on retail prices between $5-$10K
per system," stated Steve Guillen, President & CEO at MedX Health Corp.
"I have used [MoleMate/SIMSYS] for six years and have found it an
invaluable tool. I chose this technology because it gives me extra
information about my patients' suspicious moles and lesions through the
additional views of the skin and helps me and the patients to come to a
more informed decision about removal." ― Dr. R.H. Falcon, Dermatologist, New York, NY
About MoleMate & SIMSYS
The Health Canada approval of MoleMate and SIMSYS Skin Imaging Systems
is a significant advance in the early detection of potentially life
threatening moles and lesions. MoleMate and SIMSYS rapidly provide
accurate images of the pigment, blood, and collagen below the mole or
lesion. MoleMate and SIMSYS are both FDA approved, and have been sold
in the European Community, the UK, Australia, and the US.
"Among the sophisticated equipment used by University of California
Irvine Melanoma Center physicians is a SIMSYS-MoleMate SIAscope, one of
the most advanced melanoma imaging systems in the world. For patients
with many moles, this computer imaging can make a big difference, it
decreases the number of biopsies needed, so they won't look like a
pincushion." - Dr. James G. Jakowatz, surgical oncologist and UC Irvine Melanoma
Center director - Dr. Janellen Smith, UC Irvine dermatologist and
co-director of the Pigmented Lesion Program, UC Irvine
MoleMate and the more robust system, SIMSYS, work with a hand-held
scanner, designed for office use, along with a specially designed
training CD. SIMSYS allows image capture and storage as well as
special features that can be used in visualizing and comparing moles.
SIMSYS will include "mole mapping" software early in 2012. Mole
mapping is a technique that physicians use on certain patients with
50-100 or more moles where the entire surface of the patient's skin is
photographed to observe changes over time and then suspicious moles can
be monitored more closely or, if necessary, removed.
MoleMate is easy to incorporate into exams, and is easy for physicians
to learn how to use via the 60-90 minute training CD, as documented in
a study with general practitioners, who significantly improved their
ability to more accurately identify suspicious moles and lesion.
The website www.simsys-molemate.com contains additional information on MoleMate and SIMSYS, including
information on the technology behind these products, as well as product
demos, and information on how other physicians have integrated the skin
cancer imaging system into their practice.
MoleMate and SIMSYS will also be presented at the American Academy of
Dermatology's 70th Annual Meeting, March 16-22, 2012, in San Diego, California, the
world's largest, most comprehensive dermatologic educational event.
"See More," with MoleMate and SIMSYS at booth #1361.
Sales in Europe and Australia & the US
MoleMate and SIMSYS are currently being sold to physicians in Europe,
the UK, Australia, and the US and now in Canada. Interested physicians
and distributors should contact MedX Health directly at www.simsys-molemate.com.
The Most Common Form of Cancer in Canada
The Canadian Cancer Society (www.cancer.ca) and Canadian Statistics confirm that skin cancer is the most common
form of cancer in Canada. Each year there are more new cases of skin
cancer than the combined incidence of cancers of the breast, prostrate,
lung and colon.
In 2011, 79,600 Canadians were diagnosed with skin cancer; which amounts
to 1/3 of all new cancers in Canada. 5,500 of these diagnoses were
malignant melanomas, the most life threatening form. Also, skin cancer
attacks all ages and in the 1990s more than 8,000 cases were reported
in patients 20-44 years of age. The survival rate for patients, whose
melanomas are detected early, before the tumor has penetrated the lower
layers of skin, is about 99 percent. The survival rate falls to 15
percent for those with advanced disease.
Proctor & Gamble, LenioMed Ltd., and ScreenCancer, Inc., are research
and commercial partners that are funding the expansion of the
underlying technology, into new consumer and wound care markets.
About MedX Health Corp.
MedX is a twelve (12) year old Canadian company, headquartered in
Mississauga, Ontario (Toronto), and is a global leader in the design,
manufacturing and distribution of quality low level laser and light
therapy technologies for use in numerous medical settings, including
rehab/chiropractic, dental, wound care, and veterinary medicine,
providing patients with drug free and non-invasive treatment of tissue
damage and pain. MedX laser and light products are FDA approved, Health
Canada cleared, and CE Mark approved for use in North America as well
as the European Union. For a complete profile of MedX Health Corp. and
its products visit www.medxhealth.com.
This press release does not constitute an offer of any securities for
sale. This press release contains certain forward-looking statements
within the meaning of applicable Canadian securities legislation.
These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including,
without limitation, the company's limited operating history and history
of losses, the inability to successfully obtain further funding, the
inability to raise capital on terms acceptable to the company, the
inability to compete effectively in the marketplace, the inability to
complete the proposed acquisition and such other risks that could cause
the actual results to differ materially from those contained in the
company's projections or forward-looking statements. All
forward-looking statements in this press release are based on
information available to the company as of the date hereof, and the
company undertakes no obligation to update forward-looking statements
to reflect events or circumstances occurring after the date of this
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy
of this press release.
SOURCE MedX Health Corp.
For further information:
President and Chief Executive Officer
MedX Health Corp. firstname.lastname@example.org
Phone: (905) 670-4428